PT - JOURNAL ARTICLE AU - Xuzhen Qin AU - Jun Shen AU - Erhei Dai AU - Haolong Li AU - Guodong Tang AU - Lixia Zhang AU - Xin Hou AU - Minya Lu AU - Xian Wu AU - Simeng Duan AU - Jingjia Zhang AU - Yongzhe Li TI - The change pattern and significance of IgM and IgG in the progress of COVID-19 disease AID - 10.1101/2020.07.20.20157446 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.20.20157446 4099 - http://medrxiv.org/content/early/2020/07/21/2020.07.20.20157446.short 4100 - http://medrxiv.org/content/early/2020/07/21/2020.07.20.20157446.full AB - Background To investigate the significance of IgM and IgG in the progress of COVID-19.Method A multicenter cross-sectional study conducted in suspected and confirmed patients from four hospitals of China and a cohort study to identify the change pattern and significance in the process of COVID-19 disease.Results A total of 571 patients were enrolled in the cross-sectional study, including 235 confirmed SARS-CoV-2 infection with 91.9% patients IgG positive and 92.3% IgM positive. 30 patients diagnosed with SARS-CoV-2 infection were enrolled in the cohort study for flowing-up in 20 days. The peak of IgM and IgG reached in 10th and 20 th day separately after symptom onset. The relationship between clinical classification and serological antibodies were analysed. The positive rate of COVID-19 IgG and IgM increased along with the clinical classification and the delay of treatment time.Conclusion We demonstrated the kinetics of IgM and IgG SARS-CoV-2 antibody in COVID-19 patients, which may contribute to explain the results of IgM and IgG SARS-CoV-2 antibody test and predict the prognosis of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by grants from CAMS Innovation Fund for Medical Sciences (CIFMS) (2020-I2M-CoV19-001, 2017-I2M-3-001 and 2017-I2M-B&R-01), the National Natural Science Foundation of China Grants (81671618, 81871302).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been approved by the ethnic committee of Peking Union Medical College Hospital. Informed consent is waived because of the use of the remaining samples.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are available from the corresponding author upon request.